不产ESBL大肠埃希菌的质粒AmpC酶基因检测和耐药性分析

Study on the Relative Analysis of AmpC Gene Strains Unproduction Extendedspectrum β-Lactamases in Escherichia Coli

目的了解临床分离的不产ESBL的大肠埃希菌质粒AmpC酶基因（DHA，ACT-1）存在状况和菌株的耐药性关系。方法自临床分离60株不产ESBL的大肠埃希菌，采用聚合酶链反应（PCR）检测质粒AmpC酶DHA，ACT-1基因。结果60株大肠埃希菌中质粒AmpC酶DHA，ACT-1基因阳性率分另q为20．O％，30．O％，产酶菌株对三代头孢药物耐药率较高，含酶抑制剂药物的敏感度尚可。结论临床分离的不产ESBL大肠埃希菌对β-内酰胺类药物耐药率较高可能与细菌携带质粒AmpC酶DHA，ACT-1基因有关。

Objective To investigate the plasmid AmpC genes （DHA,ACT-1） in Escherichia coli of unproduction extended- spectrum β-lactamases （ESBL） and the drug-resistant of strains from the clinic. Methods 60 strains of Escherichia coli of unproduction extendedspectrum β-lactamases （ESBL） were isolated from hospitalized patients,the plasmid AmpC genes （DHA,ACT-1） were detected by PCR. Results The positive rates of the DHA and ACT-1 genes were 20.0% and 30. 0% respectively. There were high positive rate of drug resistance of Ⅲ cephaloporin. Sensitivity of drugs containing enzyme in- hibitor were acceptable. Conclusion The high positive rate of drug resistance of β-lactamases would be relative to the plasmid AmpC genes （DHA,ACT-1）.